Helus Pharma IncHELP
Price$11.91

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Free Cash Flow -$70.4MTTM through 31 Mar 2025

Margins

Current

Returns

-47.7%ROE
-43.7%ROA

Balance Sheet Health

Current Ratio7.75x
Cash & Equivalents$135M

Quality Metrics

Piotroski F-Score1 / 9
Earnings-Beat Rate25.0%

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Novel Serotonergic Agonists (NSAs) Development$0
View details

Topline Phase 3 APPROACH data expected in Q4 2026; HLP004 next study design expected to be finalized by end of Q3 2026.

Financials converted at 1.4391.
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.